Wednesday, 20 August 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 20 August 2025
News

CSL spins off Seqirus, cuts jobs

Posted 19 August 2025 PM 

CSL has outlined plans to streamline the company, by cutting 15 per cent of its non-plasma centre workforce, amounting to 3,000 jobs globally, and spinning off CSL Seqirus into a separate ASX-listed company.

CEO Paul McKenzie told the FY25 earnings call this morning that demerging Seqirus would enable both companies to "focus on their core capabilities and realise simplification benefits which will drive growth, and each will have a sustainable capital structure and access to funding to pursue distinct growth opportunities."

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.